ICER finds Biogen’s new exorbitantly priced Alzheimer’s drug doesn’t match even an optimistic view of potential clinical benefits
Even with a rosy outlook on how Biogen’s new Alzheimer’s drug will help those with the debilitating and fatal disease, the Institute for Clinical and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
